Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff sold 12,726 shares of Seres Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the sale, the chief executive officer now directly owns 192,039 shares of the company’s stock, valued at $155,551.59. This represents a 6.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB traded down $0.00 during mid-day trading on Wednesday, reaching $0.83. The company had a trading volume of 292,416 shares, compared to its average volume of 1,697,303. Seres Therapeutics, Inc. has a one year low of $0.54 and a one year high of $1.53. The firm has a market cap of $141.68 million, a price-to-earnings ratio of -3.61 and a beta of 2.11. The business’s 50-day simple moving average is $0.85 and its 200 day simple moving average is $0.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. grew its position in Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after acquiring an additional 543,469 shares during the last quarter. Geode Capital Management LLC grew its position in Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after acquiring an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 222,771 shares during the last quarter. FMR LLC grew its position in Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after acquiring an additional 140,096 shares during the last quarter. Finally, State Street Corp grew its position in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 43,700 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. Chardan Capital restated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.